Lee-May Chen, MD
Gynecologic Oncology · San Francisco, CANPI 1902861883
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by GSK at 32.8% of the total. That places this record below the midpoint for gynecologic oncology clinicians in CA, where the typical reported total is $1,602.
Across 21 payments — averaging $52.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$359
- Taiho Oncology, Inc.$191
- AstraZeneca$180
- Eisai Inc.$125
- Johnson & Johnson$56
- Intuitive Surgical$54
- plus $131 from 4 others
Across 97 payments — averaging $9582.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$401K
- Genentech, Inc.$157K
- Clovis Oncology, Inc.$156K
- GSK$101K
- AstraZeneca$69K
- Seagen Inc.$19K
- plus $26K from 2 others
What the payments were for
- Speaking & faculty fees$16715%
- Travel & lodging$14914%
- Food & beverage$61656%
- Education$16515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $359 |
| Taiho Oncology, Inc. | 5 | $191 |
| AstraZeneca | 4 | $180 |
| Eisai Inc. | 1 | $125 |
| Johnson & Johnson | 1 | $56 |
| Intuitive Surgical | 1 | $54 |
| Merck | 1 | $43 |
| Caris MPI, Inc. | 1 | $39 |
| Clovis Oncology, Inc. | 1 | $36 |
| Medical Device Business Services, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$125
How this compares
$1,096 in reported general payments places this provider in the 40th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 16 | $340 |
| Prochlorperazine Maleate | 15 | $176 |
| Ondansetron Hcl | 20 | $127 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in San Francisco
- John ChanSan Francisco$2M
- Katherine FuhSan Francisco$26K
- Lejla DelicSan Francisco$16K
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.